Isofol Medical reported that the company has selected the dose for the upcoming CC-007 trial in colorectal cancer. The ongoing phase I/II trial evaluated arfolitixorin (previously Modufolin) in doses ranging from 30 to 240mg/m2, but contrary to our belief, a higher dose will not be selected for the pivotal trial.